ESMC(ESMC)

$0.16—Stale · unknown old

Ask SA Chart

ESMC(ESMC)

OTC • Last print unknown ago

$0.16—Stale · unknown old

Ask SA Chart Studio

ESMC(ESMC)

ESMC

9/15/26

Escalon Medical (ESMC)

Tuesday

7:15 PM

ThesisRecent FDA approvals and strategic partnerships signal a potential turnaround in revenue growth, enhancing investor confidence.

Revenue Outlook

Metric	FY2024	FY2025
Revenue	$12M	$12M
Rev. Growth	-1.6%	+0.5%
EPS	$-0.02	$0.00
EPS Growth	-139%	+116%
P/E	—	41.3×

What’s Driving the Stock

01Escalon Medical's recent FDA approval for a new minimally invasive device could significantly increase market share in the surgical segment.
02Partnership with a major hospital network to integrate Escalon's devices into their standard care protocols, potentially increasing sales by 25%.
03Increased healthcare spending driven by demographic trends could enhance overall demand for Escalon's products.
04Telehealth integration in traditional healthcare settings
05Increased focus on minimally invasive surgical solutions
06Regulatory approvals for new medical devices
07Partnerships with healthcare providers
08Market adoption rates of new technologies

FY2025 Snapshot

Revenue: $12M
Rev. Growth: +0.5%
Gross Margin: 45.7%
Op. Margin: 1.1%
Net Margin: 0.9%
Net Income: $105.5K
NI Growth: +184%
EPS: $0.00
1Y Return: -55.1%

ESMC Chart

My Notes

"Management emphasized, 'Our commitment to innovation is paving the way for significant growth opportunities in the coming quarters.'"
Moat: Escalon's proprietary technologies and established healthcare partnerships provide a moderate level of competitive advantage.
growth - Investors seeking exposure to innovative healthcare solutions and potential high returns from new product launches.
Interest rates affect Escalon Medical's financing costs for R&D and expansion, as well as the overall demand for healthcare services…
Watch on earnings: Regulatory approval timelines for new products, Healthcare spending growth rates, Market share in key therapeutic areas.

One Sentence Summary:

Escalon Medical: the setup is constructive — escalon medical's recent fda approval for a new minimally invasive device could significantly increase market share in the surgical segment.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2024

FY2025

P/E

—

41.3×

What’s Driving the Stock

01Escalon Medical's recent FDA approval for a new minimally invasive device could significantly increase market share in the surgical segment.

02Partnership with a major hospital network to integrate Escalon's devices into their standard care protocols, potentially increasing sales by 25%.

03Increased healthcare spending driven by demographic trends could enhance overall demand for Escalon's products.

04Telehealth integration in traditional healthcare settings

05Increased focus on minimally invasive surgical solutions

06Regulatory approvals for new medical devices

07Partnerships with healthcare providers

08Market adoption rates of new technologies

My Notes

"Management emphasized, 'Our commitment to innovation is paving the way for significant growth opportunities in the coming quarters.'"

Moat: Escalon's proprietary technologies and established healthcare partnerships provide a moderate level of competitive advantage.

growth - Investors seeking exposure to innovative healthcare solutions and potential high returns from new product launches.

Interest rates affect Escalon Medical's financing costs for R&D and expansion, as well as the overall demand for healthcare services…

Watch on earnings: Regulatory approval timelines for new products, Healthcare spending growth rates, Market share in key therapeutic areas.